Trends in Cancer Mortality Among Adolescents and Young Adults in Brazil

Cancer incidence, mortality, and survivorship in African women: a comparative analysis (2016-2020)

Objectives

This research aims to provide concrete insight into cancer incidence, mortality, and survivorship dynamics among African women between 2016 and 2020.

Methods

The study computes the Mortality-to-Incidence Ratio (MIR) for 53 countries in Africa with available mortality and incidence data. It uses relevant Life Tables to obtain the 5-year Relative Survival rate for women in different age cohorts based on General Survival Rate and 5-year Cancer Prevalence data from the World Health Organization (WHO). The study performs an analysis of variance tests.

Results

The results of the initial data analysis show that women in the top economies in Africa have the highest cancer incidence and mortality. The study also finds that women in Northern and Southern African countries have higher relative survival rates and lower MIR than other African regions. ANOVA results confirm statistically significant differences in 5-year relative survival across the African regions. The relative survival at 5 years was an average of 45% across all age groups within the continent although relative survival is highest among females aged 5-19 and 80-84. The lowest relative survival rates are seen for infants (0-4), adolescents and young adults (25-29), and the very elderly (85+).

Conclusion

The study concludes that while cancer incidence in Africa is linked to affluence, survival is very challenging, especially for the least developed economies in Western, Eastern, and Central Africa. The results indicate the need for crucial intervention in the continent concerning awareness, research, and data collection methodology.

Mortality trend and analysis of potential years of life lost due to leukemia and lymphoma in Brazil and Mato Grosso

OBJECTIVE

To estimate the mortality trend and to analyze the potential years of life lost (PYLL) due to leukemias and lymphomas in Brazil and Mato Grosso, from 2001 to 2019.

METHODS

Time-series study on deaths from leukemias and lymphomas with data obtained from the Mortality Information System. Trends were calculated by age group by the Joinpoint regression method, using calendar year as regressor variable, estimated annual percentage change (APC) and mean annual percentage change, considering 95% confidence intervals. PYLL rates were collected from the Cancer Mortality Atlas.

RESULTS

In Brazil, the mortality rate trend remained stable for both diseases in the period: leukemias (APC=0.2; 95%CI 0.0-0.3) and lymphomas (APC=0.2; 95%CI 0.4-0.1). In Mato Grosso state, the rate for leukemias was also stable (APC=0.3; 95%CI 1.0-1.6). For lymphomas, the trend was ascendant (APC=2.3; 95%CI 0.5-4.2), but descending among people younger than 59 years. For leukemias, PYLL rates were 64 and 65/100,000 in Brazil and Mato Grosso, respectively. For lymphomas, 27 and 22/100,000, respectively, with the highest rates found among males.

CONCLUSION

The behavior of mortality rates from leukemia and lymphoma in Mato Grosso was different from that observed nationally, with an upward trend for lymphomas and no differences between age groups for both diseases. PYLL rates for leukemias were similar, while for lymphomas they were higher among men and lower in Mato Grosso when compared to Brazil.

Tendência de mortalidade e análise de anos potenciais de vida perdidos por leucemias e linfomas no Brasil e em Mato Grosso

RESUMO: Objetivos: Estimar a tendência de mortalidade e analisar os anos potenciais de vida perdidos (APVP) por leucemias e linfomas no Brasil e em Mato Grosso, entre os anos de 2001 e 2019. Métodos: Estudo de série temporal de óbitos por leucemias e linfomas obtidos do Sistema de Informação sobre Mortalidade. As tendências foram calculadas por faixa etária pelo método de regressão joinpoint, usando ano calendário como variável regressora, e estimaram-se a variação percentual anual (APC) e a variação percentual média anual, considerando intervalos de confiança de 95% (IC95%). As taxas de APVP foram coletadas do Atlas de Mortalidade por Câncer. Resultados: No Brasil, a tendência da taxa de mortalidade apresentou estabilidade para ambos os agravos, leucemias (APC=0,2; IC95% 0,0–0,3) e linfomas (APC=0,2; IC95% 0,4–0,1). No estado, a taxa por leucemias também apontou estabilidade (APC=0,3; IC95% 1,0–1,6). Para os linfomas, a tendência foi de aumento (APC=2,3; IC95% 0,5–4,2), contudo tendência decrescente foi observada entre aqueles com menos de 59 anos. Para leucemias, as taxas de APVP foram de 64 e 65/100 mil no Brasil e em Mato Grosso, respectivamente. Para linfomas, esses valores foram de 27 e 22/100 mil, respectivamente, sendo as maiores taxas encontradas no sexo masculino. Conclusão: As taxas de mortalidade por leucemias e linfomas em Mato Grosso apresentam comportamento diferente do observado nacionalmente, com tendência crescente para linfomas e sem diferenças entre as faixas etárias, para ambos os agravos. As taxas de APVP por leucemias foram semelhantes, no entanto para os linfomas foram maiores entre os homens e menores para o estado, quando comparadas com as do Brasil.

Tendências da mortalidade por câncer de colo no Brasil em 5 anos (2012-2016)

RESUMO O câncer do colo uterino é uma importante causa de morte no Brasil. O objetivo deste estudo é avaliar a mortalidade por esse câncer na população brasileira, entre 2012 e 2016, conhecendo a mortalidade nos grupos etários e nas diferentes regiões. Foi realizado um estudo de corte transversal descritivo. Os dados foram obtidos pelo Sistema de Informações sobre Mortalidade. Entre 2012 e 2016, o total de óbitos por câncer do colo do útero foi de 27.716 casos. A taxa de mortalidade específica para o Brasil passou de 6,86 para 7,18. O crescimento do coeficiente de mortalidade foi de 4,6%. Nas mulheres abaixo de 25 anos, observaram-se 189 mortes, o que equivale a 0,68% do total. Entre 25 e 64 anos, houve 18.574 óbitos (67,02%), e 8.950 mortes no grupo acima de 64 anos (32,29%). O maior percentual de óbitos ocorreu na faixa etária de 50-54 anos. A região Norte apresentou os maiores índices de óbitos e taxas de mortalidade, e o Sul o maior índice de crescimento. A mortalidade por câncer do colo uterino no Brasil apresentou crescimento durante os anos observados, com mais óbitos entre 50-54 anos. A região Sul apresentou o maior crescimento nas taxas de mortalidade.

Trends in cervical cancer mortality in Brazil in 5 years (2012-2016)

RESUMO O câncer do colo uterino é uma importante causa de morte no Brasil. O objetivo deste estudo é avaliar a mortalidade por esse câncer na população brasileira, entre 2012 e 2016, conhecendo a mortalidade nos grupos etários e nas diferentes regiões. Foi realizado um estudo de corte transversal descritivo. Os dados foram obtidos pelo Sistema de Informações sobre Mortalidade. Entre 2012 e 2016, o total de óbitos por câncer do colo do útero foi de 27.716 casos. A taxa de mortalidade específica para o Brasil passou de 6,86 para 7,18. O crescimento do coeficiente de mortalidade foi de 4,6%. Nas mulheres abaixo de 25 anos, observaram-se 189 mortes, o que equivale a 0,68% do total. Entre 25 e 64 anos, houve 18.574 óbitos (67,02%), e 8.950 mortes no grupo acima de 64 anos (32,29%). O maior percentual de óbitos ocorreu na faixa etária de 50-54 anos. A região Norte apresentou os maiores índices de óbitos e taxas de mortalidade, e o Sul o maior índice de crescimento. A mortalidade por câncer do colo uterino no Brasil apresentou crescimento durante os anos observados, com mais óbitos entre 50-54 anos. A região Sul apresentou o maior crescimento nas taxas de mortalidade.

Advances in targeted therapy for malignant lymphoma

The incidence of lymphoma has gradually increased over previous decades, and it ranks among the ten most prevalent cancers worldwide. With the development of targeted therapeutic strategies, though a subset of lymphoma patients has become curable, the treatment of refractory and relapsed diseases remains challenging. Many efforts have been made to explore new targets and to develop corresponding therapies. In addition to novel antibodies targeting surface antigens and small molecular inhibitors targeting oncogenic signaling pathways and tumor suppressors, immune checkpoint inhibitors and chimeric antigen receptor T-cells have been rapidly developed to target the tumor microenvironment. Although these targeted agents have shown great success in treating lymphoma patients, adverse events should be noted. The selection of the most suitable candidates, optimal dosage, and effective combinations warrant further investigation. In this review, we systematically outlined the advances in targeted therapy for malignant lymphoma, providing a clinical rationale for mechanism-based lymphoma treatment in the era of precision medicine.

Acute lymphoid and myeloid leukemia in a Brazilian Amazon population: Epidemiology and predictors of comorbidity and deaths

Introduction

Leukemia is the most common cancer in children and has the highest rates of incidence in industrialized countries, followed by developing countries. This epidemiologic profile can mainly be attributed to the availability of diagnostic resources. In Brazil, leukemia diagnosis is a challenge due to financial viability, lack of hemovigilance services in isolated regions and the vast size of the territory. Its incidence in the state of Amazonas has been increasing since 2010. Therefore, this study aims to describe the epidemiological pattern and spatial distribution of patients with acute lymphoid leukemia and acute myeloid leukemia in Amazonas and identify the predictors of comorbidity and death.

Materials and methods

A retrospective cross-sectional study was carried out based on patients’ data which was obtained from the database of a referral center for the period of 2005 to 2015. Variables included age, gender, ethnicity, civil status, schooling, income, location of residence, subtype of leukemia, comorbidities, and date of death. The spatial distribution was performed using QGIS v.2.18. Stata software was used for univariable and multivariable logistic regression to evaluate the association between both comorbidities and death for all characteristic groups of ALL and AML.

Results

The group that was studied was composed of 577 ALL and 266 AML patients. For both, most patients were male, with a schooling period of 1–4 years, received<1 minimum wage, and lived mostly in Manaus, followed by the municipality of Tefé. There was no association between the development of comorbidities and analyzed variables in patients with ALL. AML patients that were >60 years old and with family history of the disease had the highest risk of developing comorbidities (OR = 5.06, p = 0.038; OR = 2.44, p = 0.041, respectively). Furthermore, patients with ALL and in the 41-50-year age group had a higher risk of death (OR = 31.12; p = 0.001). No association between death and explanatory variables were found in patients with AML. In addition, significant difference was observed in time to death (chi2 = 4,098.32, p = 0.000), with 50% of patients with AML dying within two years after diagnosis, whereas in ALL, this percentual of death only is reached in approximately 5 years.

Conclusion

Our study describes the data of patients with acute leukemia in Amazonas, a remote region in the north of Brazil. In addition, it highlights the importance of hemovigilance in an Amazon region state, while focusing on peripheral areas which don't have prevention, diagnosis and treatment tools for this disease.

Incidence and mortality of bone cancer among children, adolescents and young adults of Brazil

OBJECTIVES

Bone cancers occur frequently in children, adolescents, and young adults aging 15 to 29 years. Osteosarcoma and Ewing sarcoma are the most frequent subtypes in this population. The aim of this study was to describe incidence and mortality trends of bone cancers among Brazilian children, adolescents and young adults.

METHODS

Incidence information was obtained from 23 population-based cancer registries. Mortality data were extracted from the Atlas of Cancer Mortality from 1979 to 2013. Specific and adjusted rates per million were analyzed according to gender, morphology and age at diagnosis. Median rates were used as a measure of central tendency. Joinpoint regression was applied to analyze trends.

RESULTS

Median incidence rates were 5.74 and 11.25 cases per million in children and young adults respectively. Osteosarcoma in the 15-19 years aged group had the highest incidence rates. Stable incidence rates were observed among five registries in 0-14 year's age group. Four registries had a decreased incidence trend among adolescents and young adults. Median mortality rates were 1.22 and 5.07 deaths per million in children and young adults respectively. Increased mortality was observed on the North and Northeast regions. Decreased mortality trends were seen in the South (children) and Southeast (adolescents and young adults).

CONCLUSION

Osteosarcoma and Ewing Sarcoma are the most incident bone cancers in all Brazilian regions. Bone cancers showed incidence and mortality patterns variation within the geographic regions and across age groups, although not significant. Despite limitations, it is crucial to monitor cancer epidemiology trends across geographic Brazilian regions.